Trial site
The Blavatnik Family ? Chelsea Medical Center at Mount Sinai
New York, New York 10011, United StatesNot linked to an institution yet
- 7running trials
- 1closed trial
The trials here
What the 8 trials at this site are about, from their registry records.
- Phase
- Phase 33 trials
- Phase 12 trials
- Phase 1/21 trial
- Status
- Recruiting4 trials
- Active, not recruiting3 trials
- Completed1 trial
- Lead sponsor
- Janssen Research & Development, LLC2 trials
- Allarity Therapeutics1 trial
- Genentech, Inc.1 trial
- GOG Foundation1 trial
- Hoffmann-La Roche1 trial
- and 2 more
Running trials
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· Phase 3· Hoffmann-La Roche· Source
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· Phase 3· LeonaBio· Source
Contact: Amy Tiersten
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT05306340· Phase 3· Genentech, Inc.· Source
Active, not recruiting
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
NCT05338775· Phase 1· Janssen Research & Development, LLC· Source
Recruiting
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
NCT04831580· GOG Foundation· Source
Contact: Neha Kumarley
Active, not recruiting
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
NCT04108195· Phase 1· Janssen Research & Development, LLC· Source
Recruiting
Clinical Pre-screening Protocol for Ovarian Cancer
NCT03877796· Allarity Therapeutics· Source
Contact: Neha Kumarley
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error